Announcements Trials

Browse Landscape

Phase

Status

Completed 68 Terminated 8 Unknown 3 Withdrawn 2 Active not recruiting 2 Recruiting 1 Available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 1

Interventions

pembrolizumab 567 Specimen Handling 487 Carboplatin 456 Magnetic Resonance Spectroscopy 442 Cyclophosphamide 418 Cisplatin 412 Radiotherapy 353 Gemcitabine 318 Bevacizumab 317 Paclitaxel 304 Biopsy 291 Drug Therapy 286 Blood Specimen Collection 249 Capecitabine 244 Oxaliplatin 242 fludarabine 238 Nivolumab 236 venetoclax 227 Injections 214 Docetaxel 209 Fluorouracil 204 Dexamethasone 187 Radiosurgery 182 Rituximab 162 Pemetrexed 160 Standard of Care 156 Surgical Procedures, Operative 148 durvalumab 146 atezolizumab 146 tislelizumab 140

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × tipifarnib × Clear all

NCT06540963 2026-04-28

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Milton S. Hershey Medical Center

Phase 2 Recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡